A leading U.S. clinical organization.It has presented a study to track prevalence and have an effect on COVID-19 infection in approximately 16,000 pregnant women in seven countries, adding India.The test will be applied to women during pregnancy and 12 months after delivery to compare maternal, fetal and neonatal outcomes of inflamed participants with the virus with those of pregnant women who have not become inflamed, the National Institute of Health (NIH) said, leading the test launch Tuesday.
The participating countries are India, Bangladesh, Pakistan, Kenya, Zambia, the Democratic Republic of the Congo and Guatemala, he said.Institute of Child Health and Human Development (NICHD), Eunice Kennedy Shriver.
During childbirth, women enrolled in the test will get an antibody test to determine if they have been exposed to SARS-CoV-2, the virus that causes COVID-19, the NIH said in a statement.Researchers hope to know if the infection increases the threat of headaches such as prematurity, fetal expansion delay, stillbirth, newborn death and birth defects.
They also hope to evaluate participants’ wisdom and attitudes about COVID-19 pregnancy, adding safety, protective practices, and prenatal care.
Women on the test will also be invited to participate in follow-up research on whether maternal SARS-CoV-2 infection influences the baby’s outcomes, such as cerebral palsy, developmental delays, and baby abnormalities.hearing and vision, the NIH said.
Get live inventory costs from BSE, NSE, US market.But it’s not the first time Like it on Facebook and stay with us on Twitter.
Financial Express is already on Telegram. Click here to subscribe to our channel and stay up to date with the latest news and updates from Biz.